,trastuzumab deruxtecan
roche,astrazeneca,daiichi sankyo
['destiny-breast03', 'breast', 'trastuzumab', 'destiny,breast,03', 'mbc']
trastuzumab deruxtecan (t-dxd) versus trastuzumab emtansine (t-dm1) in patients (pts) with her2-positive (her2+) unresectable and/or metastatic breast cancer (mbc): safety follow-up of the randomized, phase 3 study destiny-breast03. #asco22 
Medicina Interna - Oncología Clínica - Profesor Titular @UPBColombia - Clínica Astorga. #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis